MitoSENS Allotopic Expression — Gene Therapy & Genetic Interventions
Nuclear expression of mitochondrial genes to protect against mutations in mitochondrial DNA that accumulate with age.
Overview
MitoSENS (Mitochondrial SENS) is an approach pioneered by the SENS Research Foundation to address age-related mitochondrial DNA (mtDNA) mutations. The strategy involves expressing nuclear-encoded, codon-optimized copies of all 13 mtDNA-encoded proteins with mitochondrial targeting sequences (allotopic expression). This makes cells independent of their mtDNA, rendering mtDNA mutations harmless. Proof-of-concept has been demonstrated for ATP6 and ATP8 genes in human cell lines. The approach builds on natural precedent: evolution has already relocated ~1,500 mitochondrial genes to the nucleus over evolutionary time.
Indications
- Age-related mitochondrial DNA mutation accumulation
- Mitochondrial myopathy
- Leber hereditary optic neuropathy (LHON) - related approach already in trials
- MELAS syndrome
- Age-related mitochondrial dysfunction
Mechanism of Action
Codon-optimized versions of mtDNA genes are expressed from nuclear chromosomes using standard transcription/translation machinery
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| AAV-allotopic mtDNA genes | Study-specific | Single treatment | Preclinical; targeting individual or multiple mt genes |
Safety & Contraindications
- Protein import into mitochondria must be efficient to avoid mislocalized protein accumulation
- Hydrophobic mitochondrial proteins are difficult to express and import from the nucleus
- Only 2 of 13 mtDNA genes (ATP6, ATP8) have been successfully expressed allotopically
- Proof-of-concept for remaining 11 genes (especially Complex I subunits) remains undemonstrated
- LHON gene therapy (GenSight ND4) provides clinical validation of the general approach
- Full allotopic expression of all 13 genes is a long-term goal